Infectious causes of cancer

Mel-Mont Medical announces the validation of its patented self-sampling technology, Mía by XytoTest®, for molecular screening using HPV-DNA and 7-Type mRNA E6/E7.

Retrieved on: 
Wednesday, August 4, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Gynaecological cancer, Sexually transmitted diseases and infections, Vaccines, Human papillomavirus infection, Cervical cancer, HPV vaccine, HspE7

KLOKKARSTUA, Norway, Aug. 4, 2021 /PRNewswire/ -- Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women's health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest®, receives clinical validation as being equally effective to clinician-collected sampling.

Key Points: 
  • "Current estimates indicate that every year 569,847 women are diagnosed with cervical cancer, and 311,365 die from the disease.
  • Cervical cancer ranks as the third most frequent cancer among women in the world," according to Globocan information center on HPV and cancer.
  • The uniqueness of Ma by XytoTest empowers sexually active women to further their self-care opportunities and pre-screen for HPV-caused cancers.
  • PreTect AS, a fully ISO 13485:2016, CE/IVD certified, and FDA registered mRNA manufacturing facility based in Klokkarstua, Norway, is a wholly-owned subsidiary of Mel-Mont Medical, Inc.

LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY

Retrieved on: 
Tuesday, August 3, 2021
Cancer, Lung cancer, Infectious causes of cancer, Neoplasms, Health, Treatment of cancer, Small-cell carcinoma

Pasadena, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) announced that its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer (SCLC) (Mirzapoiazova el al., Molecular Cancer Therapeutics, online July 12, 2021).

Key Points: 
  • A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationale for a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently Initiated at City of Hope.
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml .

Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Health, Arbutus Biopharma, ABUS, Hepadnaviridae, Infectious causes of cancer, Hepatitis B virus, Hepatitis B, Hepatitis, HBV, Coronavirus

A live webcast of the fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast .

Key Points: 
  • A live webcast of the fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast .
  • An archived replay of the webcast will be available on the Companys website after the conference.
  • Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.
  • Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Microbiology, Infectious diseases, Acid-fast bacilli, Bacterial diseases, Bacteriology, Infectious causes of cancer, Healthcare-associated infections, Nontuberculous mycobacteria, Omadacycline, Mycobacterium, Tuberculosis

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Microbiology, Infectious diseases, Acid-fast bacilli, Bacterial diseases, Bacteriology, Infectious causes of cancer, Healthcare-associated infections, Nontuberculous mycobacteria, Mycobacterium, Omadacycline, Tuberculosis

Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.

Key Points: 
  • Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.
  • Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.

Debbie's Dream Foundation: Curing Stomach Cancer Announces the Return of the 2021 DDF Scholarship Essay Contest

Retrieved on: 
Monday, August 2, 2021
Abdomen, Infectious causes of cancer, Stomach cancer, Stomach

PLANTATION, Fla., Aug. 2, 2021 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces the return of the 2021 DDF Scholarship Essay Contest.

Key Points: 
  • PLANTATION, Fla., Aug. 2, 2021 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces the return of the 2021 DDF Scholarship Essay Contest.
  • The annual contest helps raise awareness about stomach cancer and inspires the next generation to explore the effects and impact of the disease.
  • Participants of each category will be provided a prompt encouraging them to explore topics based on stomach cancer, including the importance of increasing federal funding, prescreening, and more.
  • "The contest allows students to understand this disease better and hopefully be motivated to educate their peers on the risks of stomach cancer.

Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, July 29, 2021
Medical specialties, Hepadnaviridae, Arbutus Biopharma, ABUS, Infectious causes of cancer, Infectious diseases, Clinical medicine, Hepatitis B

Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 2719108.

Key Points: 
  • Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 2719108.
  • Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.
  • The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection.
  • Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Clinical trials, Health, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Papillomavirus, Vaccines, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Clinical trial, HspE7

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test

Retrieved on: 
Wednesday, July 28, 2021
Biotechnology, Other Health, Health, General Health, Women, Oncology, Other Science, Medical devices, Research, Consumer, Science, Cancer, Infectious causes of cancer, Human papillomavirus infection, Positive and negative predictive values, Cervical screening, HPV-positive oropharyngeal cancer

In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.

Key Points: 
  • In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.
  • The confidence that a positive test result truly indicated presence of disease (positive predictive value) was about the same for both LuViva (35%) and HPV (37%).
  • According to new U.S. guidelines, women with this high a likelihood of cervical disease or higher need to either have tissue removed for a definitive diagnosis or consider immediate treatment.
  • The Companys first product is the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care.

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3

Retrieved on: 
Wednesday, July 28, 2021
Tyrosine kinase receptors, Clusters of differentiation, Infectious causes of cancer, Fibroblast growth factor receptor 3, Bladder cancer, Branches of biology, Cancer, Radiation therapy, Physical sciences, Radiation, Fibroblast growth factor receptor, Natural sciences

We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.

Key Points: 
  • We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.
  • While the currently approved pan-FGFR inhibitor for bladder cancer requires the presence of a specific mutation, our approach requires only over-expression of FGFR3.
  • The information that Fusion posts on this website could be deemed to be material information.
  • As a result, Fusion encourages investors, media and others interested to review the information that Fusion posts there on a regular basis.